Zomedica Pharmaceuticals Valuation
| ZOM Stock | USD 0.12 0 2.50% |
Zomedica Pharmaceuticals seems to be undervalued based on Macroaxis valuation methodology. Our model calculates the value of Zomedica Pharmaceuticals from examining the company fundamentals such as Current Valuation of 47.11 M, return on asset of -0.0929, and Profit Margin of (2.15) % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Zomedica Pharmaceuticals' valuation include:
Price Book 0.601 | Enterprise Value 47.1 M | Enterprise Value Ebitda (7.19) | Price Sales 4.6748 | Enterprise Value Revenue 1.7626 |
Undervalued
Today
Please note that Zomedica Pharmaceuticals' price fluctuation is dangerous at this time. Calculation of the real value of Zomedica Pharmaceuticals is based on 3 months time horizon. Increasing Zomedica Pharmaceuticals' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Zomedica stock is determined by what a typical buyer is willing to pay for full or partial control of Zomedica Pharmaceuticals Corp. Since Zomedica Pharmaceuticals is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Zomedica Stock. However, Zomedica Pharmaceuticals' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.12 | Real 1.59 | Target 6.0 | Hype 0.12 |
The intrinsic value of Zomedica Pharmaceuticals' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Zomedica Pharmaceuticals' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Zomedica Pharmaceuticals Corp helps investors to forecast how Zomedica stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Zomedica Pharmaceuticals more accurately as focusing exclusively on Zomedica Pharmaceuticals' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Zomedica Pharmaceuticals' intrinsic value based on its ongoing forecasts of Zomedica Pharmaceuticals' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Zomedica Pharmaceuticals' closest peers.
Zomedica Pharmaceuticals Cash |
|
Zomedica Valuation Drivers Correlation
Many accounts on the financial statements of Zomedica Pharmaceuticals are highly interrelated and sometimes correlated. Consequently, when conducting Zomedica's valuation analysis, one should examine all of the accounts reported to obtain a complete picture of its financial situation. We provide a unique feature to present a conventional correlation table purposely composed against different valuation-related drivers of Zomedica
Click cells to compare fundamentals
Zomedica Valuation Trend
Knowing Zomedica Pharmaceuticals' actual value is paramount for traders when making sound investment determinations. Using both Zomedica Pharmaceuticals' enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Zomedica Pharmaceuticals Total Value Analysis
Zomedica Pharmaceuticals Corp is at this time estimated to have company total value of 47.11 M with market capitalization of 147.6 M, debt of 2.73 M, and cash on hands of 27.4 M. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the Zomedica Pharmaceuticals fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
47.11 M | 147.6 M | 2.73 M | 27.4 M |
Zomedica Pharmaceuticals Investor Information
The company has Price to Book (P/B) ratio of 0.6. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Zomedica Pharmaceuticals recorded a loss per share of 0.06. The entity had not issued any dividends in recent years. Based on the key indicators related to Zomedica Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Zomedica Pharmaceuticals Corp is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Zomedica Pharmaceuticals Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Zomedica Pharmaceuticals has an asset utilization ratio of 9.95 percent. This suggests that the Company is making $0.0995 for each dollar of assets. An increasing asset utilization means that Zomedica Pharmaceuticals Corp is more efficient with each dollar of assets it utilizes for everyday operations.Zomedica Pharmaceuticals Ownership Allocation
Zomedica Pharmaceuticals Corp retains a total of 997.95 Million outstanding shares. Roughly 89.97 (%) of Zomedica Pharmaceuticals outstanding shares are held by general public with 1.7 % owned by insiders and only 8.33 percent by institutional investors. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.Zomedica Pharmaceuticals Profitability Analysis
The company reported the last year's revenue of 25.19 M. Reported Net Loss for the year was (34.53 M) with profit before taxes, overhead, and interest of 13.65 M.About Zomedica Pharmaceuticals Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Zomedica Pharmaceuticals Corp. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Zomedica Pharmaceuticals based exclusively on its fundamental and basic technical indicators. By analyzing Zomedica Pharmaceuticals's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Zomedica Pharmaceuticals's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Zomedica Pharmaceuticals. We calculate exposure to Zomedica Pharmaceuticals's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Zomedica Pharmaceuticals's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 17.3 M | 18.2 M | |
| Pretax Profit Margin | (1.42) | (1.49) | |
| Operating Profit Margin | (1.25) | (1.32) | |
| Net Loss | (1.37) | (1.44) | |
| Gross Profit Margin | 0.69 | 0.79 |
Zomedica Pharmaceuticals Growth Indicators
Investing in growth stocks can be very risky. If the company such as Zomedica Pharmaceuticals does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 979.9 M |
Zomedica Pharmaceuticals Current Valuation Indicators
Zomedica Pharmaceuticals' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Zomedica Pharmaceuticals' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Zomedica Pharmaceuticals, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Zomedica Pharmaceuticals' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Zomedica Pharmaceuticals' worth.When determining whether Zomedica Pharmaceuticals is a strong investment it is important to analyze Zomedica Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zomedica Pharmaceuticals' future performance. For an informed investment choice regarding Zomedica Stock, refer to the following important reports: Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zomedica Pharmaceuticals Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zomedica Pharmaceuticals. If investors know Zomedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zomedica Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.06) | Revenue Per Share 0.027 | Quarterly Revenue Growth 0.018 | Return On Assets (0.09) | Return On Equity (0.24) |
The market value of Zomedica Pharmaceuticals is measured differently than its book value, which is the value of Zomedica that is recorded on the company's balance sheet. Investors also form their own opinion of Zomedica Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Zomedica Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zomedica Pharmaceuticals' market value can be influenced by many factors that don't directly affect Zomedica Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Zomedica Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Zomedica Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zomedica Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.